![](https://usercontent.one/wp/medimix.be/wp-content/uploads/sites/3/2024/03/eps012-rationale-1024x576.png)
Episode 12: The RATIONALE-306 study solidifies checkpoint inhibition therapy in ESCC
The RATIONALE-306 study, a global trial involving both East Asian and Western patients, evaluates the efficacy of combining the investigator’s choice doublet chemotherapy with or without tislelizumab, a PD-L1 antibody also possessing ADC properties. Notably, this was a first-line treatment